Human Pluripotent Stem Cells: A Relevant Model to Identify Pathways Governing Thermogenic Adipocyte Generation

Xi Yao, Vincent Dani and Christian Dani*

Université Côte d’Azur, IBV, UMR CNRS/INSERM, Faculté de Médecine, Nice, France

Brown and brown-like adipocytes (BAs) are promising cell targets to counteract obesity thanks to their potential to drain and oxidize circulating glucose and triglycerides. However, the scarcity of BAs in human adults is a major limitation for energy expenditure based therapies. Enhanced characterization of BA progenitor cells (BAPs) and identification of critical pathways regulating their generation and differentiation into mature BAs would be an effective way to increase the BA mass. The identification of molecular mechanisms involved in the generation of thermogenic adipocytes is progressing substantially in mice. Much less is known in humans, thus highlighting the need for an in vitro model of human adipocyte development. Pluripotent stem cells (PSCs), i.e., embryonic stem cells and induced pluripotent stem cells, help gain insight into the different phases in the development of multiple cell types. We will discuss the capacity of human PSCs to differentiate into BAs in this review. Several groups, including ours, have reported low spontaneous adipocyte generation from PSCs. However, factors governing the differentiation of induced pluripotent stem cell-derived BA progenitors cells were recently identified, and the TGFβ signaling pathway has a pivotal role. The development of new relevant methods, such as the differentiation of hPSC-BAPs into 3D adipospheres to better mimick the lobular structure of human adipose tissue, will also be discussed. Differentiation of human PSCs into thermogenic adipocytes at high frequency provides an opportunity to characterize new targets for anti-obesity therapy.

Keywords: human induced pluripotent stem cells, brown adipocytes, adipocyte progenitors, drug discovery, cell-based therapy, obesity

INTRODUCTION

The development of obesity and associated metabolic disorders such as diabetes and heart diseases is a major health issue. Obesity results from an imbalance between calorie intake and energy expenditure. The scientific community is focusing attention on white adipose tissue (WAT) that stores energy, and on means to fight its expansion. However, modern lifestyles are often not
compatible with a reduction in energy intake. Current anti-obesity drugs to reduce energy intake may have major side effects for the patients. Bariatric surgery has proven efficient for obesity, although long-term complications and obesity relapse may occur. The identification of new anti-obesity targets is thus urgently required. In contrast to WAT, classical brown adipocytes and brown-like adipocytes (BAs) dispersed in WATs, mainly in subcutaneous fat depots, are specialized in energy expenditure thanks to their high content of mitochondria expressing the uncoupling protein-1 (UCP1) (1). Upon activation, BAs consume metabolic substrates and burn fat and sugars via uncoupling of oxidative phosphorylation, in turn inhibiting ATP synthesis (2). The ability of BAs to actively drain circulating glucose and triglycerides to oxidize them can prevent hyperglycemia and hypertriglyceridemia. BAs secrete adipokines that may also contribute to metabolic effects (3). BAs are therefore promising cell targets to counteract obesity and type-2 diabetes. However, major obstacles hamper BA-based treatment of obesity, including the scarcity of BAs in adult humans.

**HOW TO INCREASE THE MASS OF BROWN-LIKE ADIPOCYTES IN OBESE PATIENTS?**

Brown adipocytes present at birth persist only around deep organs in healthy adult humans. In addition, BA activity is lower in overweight and obese individuals than in lean ones (4). The proof-of-concept of the beneficial effects of brown fat transplantation has been achieved in rodents, where normoglycemia was restored in diabetic mice and obesity reduced in Ob/Ob mice (5–7). This has given rise to the notion of increasing the BA mass in obese patients as a therapeutic approach to counteract obesity and its associated metabolic complications. A challenge now is to identify an abundant source of human BA progenitors (BAPs) for transplantation. The generation of induced pluripotent stem cells from obese patients as an unlimited source of BAPs that could be expanded for autologous transplantation is a recently discussed option ([8–10] and see below). Another option that we discuss in the present review is to promote endogenous BA generation in obese patients. Understanding the mechanisms governing the commitment of human pluripotent stem cells toward the brown-like adipogenic lineage, as well as the differentiation of BAPs into functional BAs, should help addressing this issue.

**HUMAN CELL MODELS AVAILABLE FOR INVESTIGATING BROWN-LIKE ADIPOCYTE BIOLOGY**

The identification of molecular mechanisms involved in thermogenic adipocyte generation is progressing substantially in mice. However, much less is known in humans, thus highlighting the need for an in vitro model of human adipocyte development. Because of the rareness of BAs in adult humans, immortalized cell lines or multipotent stem cells derived from adipose tissues of young donors (hMADS cells) are the main cellular models used to identify pathways critical for adipogenesis. PAZ6 cells are preadipocytes derived from the vascular stromal fraction of infant BAT which have been immortalized ex vivo using the SV40T and t antigens (11). Human preadipocytes from adult BAT localized in deep neck fat can also be immortalized, as recently described (12). hMADS cell lines have been isolated from adipose tissues of young donors in our laboratory. They are not immortalized cells, but can be maintained for several passages in vitro thanks to the intrinsic high self-renewal capacity of stem cells (13, 14). Interestingly, hMADS cells can be converted into functional brown-like adipocytes (15). However, the features of infant hMADS dramatically decrease with aging. In addition, these cells are already committed in the adipose lineage, thus precluding the possibility of investigating the earliest steps of adipogenesis.

**PLURIPOTENT STEM CELLS REPRESENT A POWERFUL MODEL TO IDENTIFY PATHWAYS GOVERNING THERMOGENIC ADIPOCYTE DEVELOPMENT**

Pluripotent stem cells (PSCs), i.e., embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), display a quasi-unlimited self-renewal capacity and are an abundant source of multiple cell types of therapeutic interest. Some papers in the early 2000s reported the potential of human ES cells to generate adipocytes (16–18). These observations suggested that PSCs could be a valuable tool to identify pathways regulating the different steps of adipogenesis, i.e., from the generation of adipose progenitors to their differentiation into mature adipocytes. Then, Taura et al. demonstrated that human iPSCs have an adipogenic potential comparable to that of human ES cells (19). However, these authors did not address the adipogenesis efficiency and the phenotype of adipocytes generated. Surprisingly, a cocktail of hematopoietic factors allowed Nishio and colleagues to report, for the first time, the capacity of human iPSCs to generate substantial BAs (20). These findings support the idea that, as previously shown in mice (21), the BMP signaling pathway plays a critical role in human brown adipocyte generation. However, Nishio did not purify BAPs from differentiating hiPSCs and there was no evidence that the stem cells progressed through a complete adipogenic program to generate adipocytes. Ahfeldt et al. purified hiPSC-derived fibroblasts that were able to undergo differentiation into white adipocytes or BAs following forced expression of adipogenic master genes (22). This strategy allows the generation of human BAs and may be a powerful tool for drug discovery, but the question arises as to whether these cells with ectopic expression of adipogenic master genes faithfully reflect physiological adipogenesis. More recently, a procedure to isolate expandable BAPs from hiPSCs and to generate high levels of functional BAs with no gene transfer was described (8, 23, 24). West and colleagues clonally derived several white- and brown- adipocyte progenitors...
from hES cell lines and assessed their adipogenic potential when encapsulated in a biocompatible matrix approved for use in human clinical studies (25). These models provide an opportunity to make effective use of hiPSC features to identify critical pathways governing the development of brown-like adipocytes.

**HUMAN PLURIPOTENT STEM CELL COMMITMENT TOWARD THE BROWN-LIKE ADIPOGENIC LINEAGE IS NEGATIVELY REGULATED BY THE RETINOIC ACID PATHWAY**

Mohsen-Kanson and colleagues, in our laboratory, investigated factors involved in the commitment of pluripotent stem cells toward adipogenic lineages (23). Four hiPS cell lines and one hES cell line were studied for that purpose. Adipogenic markers, including UCP1, Dia2, PGC1α, and PRDM16, were detected in differentiated cultures, indicating that cells having a brown-like adipocyte gene program were spontaneously generated during differentiation. However, the adipogenesis efficiency was weak. Indeed, adipocytes were co-stained with LipidTox (for triglyceride staining) and CD73 (an adipocyte cell surface marker), and then quantified by flow cytometry (26). The data showed that the number of LipidTox+/CD73+ cells represented only 2% of cells in the differentiated cultures. Small-scale drug screening to uncover signaling pathways regulating the earliest steps of human adipogenesis revealed that the retinoic acid (RA) pathway promoted hiPSCs commitment toward the adipogenic lineage by increasing the number of LipidTox+/CD73+ cells to 15%. In contrast, expression of the brown adipocyte specific marker UCP1 was inhibited in RA-treated cultures. Together, these data support the hypothesis that RA pathway activation at an early development stage dramatically promotes the differentiation of human PSCs into the UCP1-negative adipocyte lineage, while inhibiting UCP1-positive adipocyte generation (see Figure 1). This observation is reminiscent of the critical role of RA in the early steps of mouse ES cell white adipogenesis (27, 28). The identification of RA targets could provide a means to uncover genes involved in the earliest steps of adipogenesis. The combination of computational and experimental approaches in mouse ES cells revealed an extensive network of transcription factors that might coordinate the expression of genes essential for the acquisition of adipocyte characteristics (29). This could represent a unique comprehensive resource that could be further explored to investigate human adipocyte development.

**CRITICAL ROLE OF THE TGFβ PATHWAY IN HIPSC-BA PROGENITOR DIFFERENTIATION**

Several research groups, including ours, have reported that hiPSC-BA progenitors display a low adipogenic capacity that hamper their use in cell-based therapy and basic research. In fact, Chen et al. first underlined the limited capacity of hiPSC-derived progenitors to undergo adipocyte differentiation, a feature that is often observed by authors but not always
pointed out (30). Interestingly, the low adipogenic differentiation potential is not restricted to hiPSC-derived cells as derived from human hESCs display the same feature, thus ruling out the possibility that the low hiPSC-adipogenic capacity could be due to incomplete reprogramming. The low adipogenic potential of adipose progenitors is also not dependent on the methods used to derive them from PSCs (31). Overall, these observations indicated that appropriate culture conditions had to be set up to unlock hPSC-BAP adipogenesis. Ascorbic acid, EGF, hydrocortisone, activin A and IL4 have been shown to regulate hiPSC-BAP differentiation (8, 23, 24, 32) (see Table 1). However, TGFβ signaling has a pivotal role. The TGFβ pathway has emerged as a critical anti-adipogenic player through the Smad 2/3 activation (33–35). Deletion of TGFβ receptor 1 in mice has been shown to promote brown-like adipogenesis within white adipose tissue, thus supporting a model where TGFβ receptor signaling plays a role in regulating the pool of BAPs (36). The Smad2/3 pathway was found to be active during hiPSC-BAP differentiation, suggesting that bioactive TGFβ family members were secreted, which might lock differentiation (24). In agreement with this hypothesis, Su et al. showed more recently that the expression of TGFβ-ligands and -receptors increased during the differentiation of FOXF1 mesoderm progenitors toward adipocytes during hiPSCs development (8). The anti-adipogenic role of the TGFβ pathway has also been functionally demonstrated via use of the TGFβ inhibitor SB431542 (37). Inhibition of the active Smad 2/3 pathway upon SB431542 addition during hiPSC-BAP differentiation induced a sharp increase in UCP1 expression and in the number of mature BAs (8, 24, 38). Figure 1 illustrates the regulation of brown-like adipocyte generation from hiPSCs by the retinoic acid and TGFβ pathways. Wankhade and colleagues proposed that negative regulation of PGE2/Cox-2 by TGFβ is involved in the recruitment of brown-like adipose progenitors (36). Interestingly, inhibition of the TGFβ pathway is not a prerequisite for adult adipose tissue-derived adipose progenitor differentiation. The low hiPSC-BAP adipogenic capacity compared to human adult-BAPs is reminiscent of the findings of Wang et al. who described distinct mechanisms regulating differentiation of embryonic-like and adult adipose progenitors in mice (39). Our hypothesis is that several pathways inhibit the development of PSC-BAs, which means that small molecules must be used to unlock differentiation. We also hypothesize that the current 2D culture conditions are not effective in promoting hiPSC-BAP differentiation. The development of new in vitro culture methods better mimicking the structure of human adipose tissue could now help decipher relevant regulators of BA adipogenesis.

### THE NEXT STEPS TOWARD GAINING GREATER INSIGHT INTO THE DEVELOPMENT OF HUMAN BAs: 3D ADIPOSPHERES GENERATION

The weak efficacy of hiPSC-BAP differentiation might partially be explained by the culture conditions, which do not mimic the physiological microenvironment in which cells normally reside within adipose tissue. Cells are conventionally grown as monolayers in 2D, which is out of line with the in vitro situation. Adipose tissue exhibits a complex lobular architecture that plays a functional role in adipogenesis (40). Indeed, adipose tissue is highly vascularized and made up of lobules, corresponding to clusters of adipocytes, separated from each other by a structured extracellular matrix (41). Interestingly, it has been proposed that the adipocyte browning phenomenon specifically occurs in these lobules (42). In an effort to enhance the physiological relevance of in vitro studies, 3D culture technologies and bioengineering methods for seeding different cell types in an organoid-like structure are highly promising (43–46). 3D cultures represent a bridge between traditional cell culture and live tissue. But, could these new technologies be applied to hiPSC-BAPs maintenance and differentiation? It is interesting to note that hiPSC-BAs have been generated by several teams via the formation of hiPSC-embryoids in suspension (20, 22, 23, 38). This strongly suggests that hiPSC-BAPs could be maintained in 3D culture conditions. The next challenge will be the generation of 3D hiPSC-brown-like adipospheres resembling human adipose tissue. The challenges will include to enrich hiPSC-brown-like adipospheres with endothelial cells and macrophages embedded in an extracellular matrix allowing functional bidirectional interactions between the microenvironment and adipocytes.

### CONCLUSIONS

Human pluripotent stem cells provide an opportunity to characterize pathways that play a role in the different steps of thermogenic adipocyte development. Some factors have been identified, but their impact on other hiPSC-derived cells of interest such as white adipocytes, endothelial cells and macrophages, has yet to be determined and integrated in a relevant model. 3D culture of hiPSC-adipospheres in which BAs interact with cell types that are present in the adipose tissue microenvironment will provide a more suitable physiological in vitro condition that should lead to the identification of druggable pathways to counteract obesity and its associated metabolic disorders.
Yao et al.  

Human Pluripotent Stem Cells-Adipogenesis

AUTHOR CONTRIBUTIONS

XY, VD, and CD contributed to the conception and design of the review. XY and VD generated the data shown. CD wrote the manuscript. All authors approved the submitted version.

REFERENCES

1. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. (2014) 156:20–44. doi: 10.1016/j.cell.2013.12.012
2. Himms-Hagen J. Brown adipose tissue thermogenesis: interdisciplinary studies. Faseb J. (1990) 4:2890–8. doi: 10.1096/fasebj.4.11.2199286
3. Villarroya F, Giralt M. The beneficial effects of brown fat transplantation: further evidence of an endocrine role of brown adipose tissue. Endocrinology. (2015) 156:2388–70. doi: 10.1210/en.2015-1423
4. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts KM, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. (2013) 123:215–23. doi: 10.1172/JCI62308
5. Liu X, Wang S, You Y, Meng M, Zheng Z, Dong M, et al. Brown adipose tissue transplantation reverses obesity in Ob/Ob mice. Endocrinology. (2015) 156:2461–9. doi: 10.1210/en.2014-1598
6. Min SY, Kady J, Nam M, Rojas-Rodriguez R, Berkenwald A, Kim JH, et al. Human “brîte/beige” adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice. Nat Med. (2016) 22:312–8. doi: 10.1038/nm.4031
7. Su S, Guntur AR, Nguyen DC, Fakory SS, Doucette CC, Leech C, et al. A renewable source of human beige adipocytes for development of therapeutics to treat metabolic syndrome. Cell Rep. (2018) 25:3215–28 e3219. doi: 10.1016/j.celrep.2018.11.037
8. Brown AC. Brown adipocytes from induced pluripotent stem cells-how far have we come? Ann N Y Acad Sci. (2019). doi: 10.1111/nyas.14257. [Epub ahead of print].
9. Yao X, Salingova B, Dani C. Brown-like adipocyte progenitors derived from human iPS cells: a new tool for anti-obesity drug discovery and cell-based therapy? Handb Exp Pharmacol. (2019) 251:97–105. doi: 10.1007/10674_2018_118
10. Kazantzi M, Takahashi V, Hinkle K, Kota S, Zilberfarb V, Issad T, et al. PAZ6 cells constitute a representative model for human brown pre-adipocytes. Front Endocrinol. (2012) 3:3.3. doi: 10.3389/fendo.2012.00013
11. Xue R, Lynes MD, Dreyfuss JM, Shamsi F, Schulz TJ, Zhang H, et al. Clonal analyses and gene profiling identify genetic biomarkers of the thermogenic potential of human brown and white preadipocytes. Nat Med. (2015) 21:760–8. doi: 10.1038/nm.3881
12. Rodriguez A-M, Pisaní D, Dechesne CA, Turc-Carel C, Kurzenne-J Y, Wdziekonski B, et al. Transplantation of a multipotent cell population from human adipose tissue induces dystrophic expression in the immunocompetent mdx mouse. J Exp Med. (2005) 201:1397–405. doi: 10.1084/jem.20042224
13. Zaragosi LE, Ailhaud G, Dani C. Autocrine fibroblast growth factor 2 signaling is critical for self-renewal of human multipotent adipose-derived stem cells. Stem Cells. (2006) 24:2412–9. doi: 10.1634/stemcells.2006-0006
14. Elabd C, Chiellini C, Carmona M, Galitzky J, Cochet O, Petersen R, et al. Human multipotent adipose-derived stem cells differentiate into functional brown adipocytes. Stem Cells. (2009) 27:2753–60. doi: 10.1002/stem.200
15. Xiong C, Xie CQ, Zhang L, Zhang J, Xu K, Fu M, et al. Derivation of adipocytes from human embryonic stem cells. Stem Cells Dev. (2005) 14:671–5. doi: 10.1089/scd.2005.14.671
16. van Harmelen V, Aström G, Stromberg A, Sjolín E, Dicker A, Hovatta O, et al. Differential lipolytic regulation in human embryonic stem cell-derived adipocytes. Obesity. (2007) 15:846–52. doi: 10.1080/0745727070116813
17. 18. Hannan NR, Wolvetang EJ. Adipocyte differentiation in human embryonic stem cells transduced with Oct4 shRNA lentivirus. Stem Cells Dev. (2009) 18:653–60. doi: 10.1089/scd.2008.0160
19. Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, et al. Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells. FEBS Lett. (2009) 583:1029–33. doi: 10.1016/j.febslet.2009.02.031
20. Nishio M, Yoneshio T, Nakahara M, Suzuki S, Saeki K, Hasegawa M, et al. Production of functional classical brown adipocytes from human pluripotent stem cells using specific hemopoietin cocktail without gene transfer. Cell Metab. (2012) 16:394–406. doi: 10.1016/j.cmet.2012.09.001
21. Tseng YH, Vaz M, Chew K, Huang TL, Winnay JN, Taniuchi CM, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature. (2008) 454:1000–4. doi: 10.1038/nature07221
22. Ahfeldt T, Schinzel RT, Lee YK, Hendrickson D, Kaplan A, Lum DH, et al. Programming human pluripotent stem cells into white and brown adipocytes. Nat Cell Biol. (2012) 14:209–19. doi: 10.1038/ncb2411
23. Mohsen-Kanson T, Hafner AL, Vdziekonski B, Takashima Y, Villageois P, Carriere A, et al. Differentiation of human induced pluripotent stem cells into brown and white adipocytes: role of Pax3. Stem Cells. (2014) 32:1459–67. doi: 10.1002/stem.1607
24. Hafner AL, Contet J, Ravaud C, Yao X, Villageois P, Suknuntha K, et al. Brown-like adipose progenitors derived from human induced pluripotent stem cells: Identification of critical pathways governing their adipogenic capacity. Sci Rep. (2016) 6:32490. doi: 10.1038/srep32490
25. West MD, Chang CF, Larocca D, Li J, Jiang J, Sim P, et al. Clonal derivation of white and brown adipocyte progenitor cell lines from human pluripotent stem cells. Stem Cell Res Ther. (2019) 10:7. doi: 10.1186/s13287-018-1087-7
26. Schaelich K, Knelangen JM, Navehrante Santos A, Fischer B, Navehrante Santos A. A simple method to sort ESC-derived adipocytes. Cytometry A. (2010) 77:990–5. doi: 10.1002/cyto.a.20953
27. Dani C, Smith A, Dessolin S, Leroy P, Staccioli L, Villageois P, et al. Differentiation of embryonic stem cells into adipocytes in vitro. J Cell Sci. (1997) 110:1279–85.
28. Kawaguchi J, Mee PJ, Smith AG. Osteogenic and chondrogenic differentiation of embryonic stem cells in response to specific growth factors. Bone. (2005) 36:758–69. doi: 10.1016/j.bone.2004.07.019
29. Billon N, Koldi R, Reimand J, Monteiro MC, Kull M, Peterson H, et al. Comprehensive transcriptome analysis of mouse embryonic stem cell adipo genesis unravels new processes of adipocyte development. Genome Biol. (2010) 11:R80. doi: 10.1186/gb-2010-11-8-r80
30. Chen Y, Pelekanos RA, Ellis RL, Horne R, Wolvetang EJ, Fisk NM. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med. (2012) 1:83–95. doi: 10.5966/sctm.2011-0022
31. Hafner AL, Dani C. Human induced pluripotent stem cells: a new source for brown and white adipocytes. World J Stem Cells. (2014) 6:467–72. doi: 10.4232/wjsci.v6.i4.467
32. Guarnini AC, Briand N, Capel E, Dumont F, Morichon R, Provost C, et al. Functional human beige adipocytes from induced pluripotent stem cells. Diabetes. (2017) 66:1470–8. doi: 10.2337/db16-1107
33. Zaragosi LE, Vdziekonski B, Villageois P, Keophiphath M, Maumus M, Tchkonia T, et al. Activin plays a critical role in proliferation and differentiation of human adipose progenitors. Diabetes. (2010) 59:2513–21. doi: 10.2337/db10-0013

FUNDING

Research related to this review in Dani’s team was supported by the French National Research Agency (grant number ANR-18-CE18-0006-01) and through the Investments for the Future (LABEX SIGNALIFE: program reference # ANR-11-LABX-0028-01).
34. Zamani N, Brown CW. Emerging roles for the transforming growth factor-β superfamily in regulating adiposity and energy expenditure. *Endocr Rev.* (2011) 32:387–403. doi: 10.1210/er.2010-0018

35. Bourlier V, Sengenes C, Zakaroff-Girard A, Decaunes P, Wdziekonski B, Galitzky J, et al. TGFβ family members are key mediators in the induction of myofibroblast phenotype of human adipose tissue progenitor cells by macrophages. *PLoS ONE.* (2012) 7:e31274. doi: 10.1371/journal.pone.0031274

36. Wankhade UD, Lee JH, Dagur PK, Yadav H, Shen M, Chen W, et al. TGF-β receptor 1 regulates progenitors that promote browning of white fat. *Mol Metab.* (2018) 16:160–71. doi: 10.1016/j.molmet.2018.07.008

37. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Mol Pharmacol.* (2002) 62:65–74. doi: 10.1124/mol.62.1.65

38. Hafner AL, Mohsen-Kanson T, Dani C. Differentiation of brown adipocyte progenitors derived from human induced pluripotent stem cells. *Methods Mol Biol.* (2018) 1773:31–9. doi: 10.1007/978-1-4939-7799-4_4

39. Wang QA, Tao C, Jiang L, Shao M, Ye R, Zhu Y, et al. Distinct regulatory mechanisms governing embryonic versus adult adipocyte maturation. *Nat Cell Biol.* (2015) 17:1099–111. doi: 10.1038/nch3217

40. Esteve D, Boulet N, Belles C, Zakaroff-Girard A, Decaunes P, Briot A, et al. Lobular architecture of human adipose tissue defines the niche and fate of progenitor cells. *Nat Commun.* (2019) 10:2549. doi: 10.1038/s41467-019-09992-3

41. Wassermann F. The development of adipose tissue. *Compr Physiol.* (1965). 87 (Suppl. 15):100.

42. Barreau C, Labit E, Guissard C, Rouquette J, Boiveau ML, Gani Koumassi S, et al. Regionalization of browning revealed by whole subcutaneous adipose tissue imaging. *Obesity.* (2016) 24:1081–9. doi: 10.1002/oby.21455

43. Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ehner D, et al. Screening out irrelevant cell-based models of disease. *Nat Rev Drug Discov.* (2016) 15:751–69. doi: 10.1038/nrd.2016.175

44. Takebe T, Zhang R, Radisic M. Synergistic engineering: organoids meet organs-on-a-chip. *Cell Stem Cell.* (2017) 21:297–300. doi: 10.1016/j.stem.2017.08.016

45. Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. *Front Pharmacol.* (2018) 9:6. doi: 10.3389/fphar.2018.00006

46. Liu C, Oikonomopoulos A, Sayed N, Wu J. Modeling human diseases with induced pluripotent stem cells from 2D to 3D and beyond. *Development.* (2018) 145:dev156166. doi: 10.1242/dev.156166

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yao, Dani and Dani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.